Hollencrest Capital Management increased its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 57.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,051 shares of the company’s stock after purchasing an additional 2,200 shares during the period. Hollencrest Capital Management’s holdings in Eli Lilly and were worth $511,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Accredited Investors Inc. increased its stake in Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after buying an additional 14 shares during the period. Oakworth Capital Inc. increased its stake in Eli Lilly and by 0.3% during the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after buying an additional 20 shares during the period. Sfmg LLC increased its stake in Eli Lilly and by 0.5% during the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after buying an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. increased its stake in Eli Lilly and by 0.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after buying an additional 24 shares during the period. Finally, YorkBridge Wealth Partners LLC increased its stake in Eli Lilly and by 0.8% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after buying an additional 24 shares during the period. 76.35% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the completion of the transaction, the senior vice president now owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 251,088 shares of company stock valued at $22,041,236. Company insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Co (NYSE:LLY) opened at $85.49 on Friday. Eli Lilly and Co has a 52-week low of $74.00 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market cap of $94,495.98, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.67 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the business posted $0.88 EPS. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. equities research analysts anticipate that Eli Lilly and Co will post 4.22 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a $0.5625 dividend. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.63%. Eli Lilly and’s dividend payout ratio is presently 98.58%.

Several equities research analysts recently weighed in on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Barclays upped their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, October 13th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Cowen reissued a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $92.75.

COPYRIGHT VIOLATION WARNING: “Hollencrest Capital Management Acquires 2,200 Shares of Eli Lilly and Co (LLY)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/20/hollencrest-capital-management-acquires-2200-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.